S1743 Symptom and Quality of Life Benefits of Achieving Deep Remission – A Real-World Survey of Patients With Ulcerative Colitis

Introduction: Ulcerative colitis (UC) treatment aims to reduce inflammation, resolve symptoms and improve quality of life (QoL). Deep remission is a target of current clinical guidelines, but it remains unclear whether achievement of deep remission offers additional benefits over partial response. We aimed to evaluate the benefits of deep remission on symptoms and QoL. Methods: Data were drawn from the Adelphi Real World UC Disease Specific Programme™, a cross-sectional survey of gastroenterologists (GIs) and their patients with UC in France, Spain, Germany, Italy, the United Kingdom and the United States, collected Feb 2023-Oct 2024. Moderate-severe patients diagnosed with UC ≥6 months and receiving treatment at survey, were included. GIs reported patient demographics, clinical status and treatment satisfaction. Patients reported treatment satisfaction and QoL via EQ-5D-5L (US tariff), EQ-VAS, the Short Inflammatory Bowel Disease Questionnaire (SIBDQ) and Work Productivity and Activity Impairment questionnaire. Patients were defined as non-remitters (NR), achieved clinical remission only (CR), or achieved both clinical and endoscopic remission (CER). CER was subdivided into deep remission (DR-CER) and not confirmed remission (NC-CER). Pairwise remission group comparisons used Bonferroni corrected t-tests and Fisher’s exact test (α = 0.05/6 = 0.0083). Regression coefficients (coef) and odds ratios (OR) compared QoL outcomes and satisfaction. Results: Among 1055 patients (NR 416, CR 117, NC-CER 273, DR-CER 249), mean (standard deviation) age was 42.1 (13.9) years, 56.5% were men. Fatigue and abdominal distension were more frequent in NR and abdominal pain and rectal bleeding were more frequent in both NR and CR than DR-CER patients (all P < 0.0083). NR had lower EQ-5D-5L (coef: -0.15) and SIBDQ scores (coef: -15.6), higher overall work (coef: 31.8) and activity impairment (coef: 28.8) than DR-CER (all P < 0.001). EQ-VAS was lower for NR (coef: -26.63, P < 0.001) and CR (coef: -8.01, P < 0.05) than DR-CER. Physician-reported (OR: NR 0.01, CR 0.01, NC-CER 0.06) and patient-reported (OR: NR 0.05, CR 0.14, NC-CER 0.28) satisfaction with treatment was lower for all groups compared to DR-CER patients (all P < 0.05). Conclusion: Deep remission in UC was associated with reduced symptom and QoL burden, work impairment and greater satisfaction compared to NR. The residual burden in CR patients highlights a need for more effective therapies to achieve deep remission.